CD30, also known as TNFRSF8 (TNF receptor superfamily member 8), is a cell membrane protein of the tumor necrosis factor receptor family and a tumor marker...
13 KB (1,665 words) - 03:34, 21 December 2023
non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL. The drug is being...
21 KB (1,998 words) - 19:56, 17 March 2024
CD153 (redirect from CD30 ligand)
receptor CD30. It plays a role in the T cell-dependent anti-mycobacterial immune response. Marín ND, García LF (January 2017). "The role of CD30 and CD153...
1 KB (102 words) - 02:09, 28 March 2022
kidney-shaped or horseshoe-shaped nuclei, prominent Golgi, and express the CD30 tumor marker protein on their surface membranes. In 2016, the World Health...
41 KB (5,218 words) - 01:14, 29 February 2024
similar to anaplastic large cell lymphoma. Type "A" is CD30 positive, while type "B" is CD30 negative. It has been described as "clinically benign but...
5 KB (352 words) - 18:31, 6 October 2023
large cell lymphoma belongs to the group of cutaneous processes that are CD30+ lymphoproliferative and are characterized by autoregressive, recurrent,...
10 KB (843 words) - 21:31, 23 January 2024
is a CD30-targeting antibody that delivers a toxin, monomethyl auristatin E, to CD30-expressing cells, has therapeutic efficacy against other CD30-expressing...
69 KB (8,143 words) - 18:36, 22 January 2024
treat cancer. Brentuximab vedotin, for example, links the chimeric anti-CD30 monoclonal antibody (cAC10) via a protease-cleavable linker to MMAE. This...
34 KB (3,138 words) - 02:17, 26 May 2024
antibodies (usually forming an antibody-drug conjugate). targeting the protein CD30 which is found on malignant cells in anaplastic large cell lymphoma and Hodgkin's...
9 KB (649 words) - 22:01, 12 August 2023
et varioliformis acuta CD30+ cutaneous T-cell lymphoma Secondary cutaneous CD30+ large cell lymphoma Non-mycosis fungoides CD30− cutaneous large T-cell...
12 KB (1,104 words) - 02:45, 23 May 2024